APNH.Y Stock Overview
Manufactures and supplies specialty and branded pharmaceutical products worldwide.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 3/6 |
Past Performance | 1/6 |
Financial Health | 5/6 |
Dividends | 3/6 |
Aspen Pharmacare Holdings Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | R10.26 |
52 Week High | R13.69 |
52 Week Low | R8.80 |
Beta | 0.60 |
11 Month Change | -7.23% |
3 Month Change | -21.14% |
1 Year Change | 11.28% |
33 Year Change | -26.35% |
5 Year Change | 27.61% |
Change since IPO | 61.57% |
Recent News & Updates
Recent updates
Shareholder Returns
APNH.Y | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | 1.2% | -4.5% | 2.3% |
1Y | 11.3% | 10.9% | 35.1% |
Return vs Industry: APNH.Y underperformed the US Pharmaceuticals industry which returned 10.9% over the past year.
Return vs Market: APNH.Y underperformed the US Market which returned 35.1% over the past year.
Price Volatility
APNH.Y volatility | |
---|---|
APNH.Y Average Weekly Movement | n/a |
Pharmaceuticals Industry Average Movement | 9.4% |
Market Average Movement | 6.2% |
10% most volatile stocks in US Market | 15.0% |
10% least volatile stocks in US Market | 2.9% |
Stable Share Price: Data is not available.
Volatility Over Time: Insufficient data to determine APNH.Y's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1850 | 9,109 | Stephen Saad | www.aspenpharma.com |
Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and supplies specialty and branded pharmaceutical products worldwide. It operates in Commercial Pharmaceuticals and Manufacturing segments. The company provides general, local, and regional anesthetic; low molecular weight heparin; regional and spinal anesthetic; and opioid analegesic under the Diprivan, Emla, Fraxiparine, Marcaine, Ultiva, and Xylocaine brand names.
Aspen Pharmacare Holdings Limited Fundamentals Summary
APNH.Y fundamental statistics | |
---|---|
Market cap | US$4.54b |
Earnings (TTM) | US$249.90m |
Revenue (TTM) | US$2.54b |
18.2x
P/E Ratio1.8x
P/S RatioIs APNH.Y overvalued?
See Fair Value and valuation analysisEarnings & Revenue
APNH.Y income statement (TTM) | |
---|---|
Revenue | R44.71b |
Cost of Revenue | R25.29b |
Gross Profit | R19.42b |
Other Expenses | R15.01b |
Earnings | R4.40b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 9.91 |
Gross Margin | 43.43% |
Net Profit Margin | 9.85% |
Debt/Equity Ratio | 42.3% |
How did APNH.Y perform over the long term?
See historical performance and comparison